Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review
Authors
Keywords
Balugrastim, Granulocyte colony-stimulating factor, Lipegfilgrastim, Neutropenia, Pegfilgrastim, Systematic review
Journal
SUPPORTIVE CARE IN CANCER
Volume 23, Issue 2, Pages 525-545
Publisher
Springer Nature
Online
2014-10-06
DOI
10.1007/s00520-014-2457-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials
- (2013) G. H. Lyman et al. ANNALS OF ONCOLOGY
- Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)
- (2013) Arash Naeim et al. BMC CANCER
- Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
- (2013) Igor Bondarenko et al. BMC CANCER
- Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice
- (2013) D. Almenar Cubells et al. EUROPEAN JOURNAL OF CANCER CARE
- Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
- (2013) Luigi Rossi et al. Therapeutics and Clinical Risk Management
- Prevention of Chemotherapy-Induced Neutropenia with Pegfilgrastim: Pharmacokinetics and Patient Outcomes
- (2012) Bing-Bing Yang et al. CHEMOTHERAPY
- Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses
- (2012) H. J. Henk et al. JOURNAL OF MEDICAL ECONOMICS
- Different Schedules of Granulocyte Growth Factor Support for Patients With Breast Cancer Receiving Adjuvant Dose-Dense Chemotherapy
- (2011) Daniel Hendler et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer
- (2011) P. Jenkins et al. ANNALS OF ONCOLOGY
- Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
- (2011) Katy L Cooper et al. BMC CANCER
- Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer
- (2011) John Pippen et al. BREAST CANCER RESEARCH AND TREATMENT
- Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia
- (2011) Emmanouil Saloustros et al. EXPERT OPINION ON PHARMACOTHERAPY
- Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis
- (2011) Nuttapong Ngamphaiboon et al. MEDICAL ONCOLOGY
- Breakthrough Febrile Neutropenia and Associated Complications in Non-Hodgkin’s Lymphoma Patients Receiving Pegfilgrastim
- (2010) Jia Hui Ng et al. ACTA HAEMATOLOGICA
- Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications
- (2010) J. Crawford et al. ANNALS OF ONCOLOGY
- Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients
- (2010) Alexandre CHAN et al. Asia-Pacific Journal of Clinical Oncology
- A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer
- (2010) Denise A. Yardley et al. Clinical Breast Cancer
- A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
- (2010) J. Randolph Hecht et al. Clinical Colorectal Cancer
- Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study
- (2010) Hiangkiat Tan et al. CURRENT MEDICAL RESEARCH AND OPINION
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- (2010) M.S. Aapro et al. EUROPEAN JOURNAL OF CANCER
- Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)
- (2010) Sibylle Loibl et al. SUPPORTIVE CARE IN CANCER
- Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG
- (2009) J. Braess et al. BLOOD
- Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia
- (2009) Mark L. Heaney et al. CANCER
- Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study
- (2009) Derek Weycker et al. CLINICAL THERAPEUTICS
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Advances in the treatment of neutropenia
- (2009) David C Dale Current Opinion in Supportive and Palliative Care
- Impact of primary prophylaxis on febrile neutropenia within community practices in the US
- (2009) Dawn Hershman et al. JOURNAL OF MEDICAL ECONOMICS
- Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study
- (2008) D. ALMENAR et al. EUROPEAN JOURNAL OF CANCER CARE
- Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303)
- (2008) Antonius A. Miller et al. Journal of Thoracic Oncology
- Pegfilgrastim ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
- (2007) G. von Minckwitz et al. ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started